Stifel Maintains Hold on Ionis Pharmaceuticals, Raises Price Target to $53
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Paul Matteis maintains a Hold rating on Ionis Pharmaceuticals (NASDAQ:IONS) and raises the price target from $50 to $53.
June 27, 2024 | 12:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Paul Matteis maintains a Hold rating on Ionis Pharmaceuticals and raises the price target from $50 to $53.
The raised price target from $50 to $53 indicates a positive outlook from the analyst, which could lead to a short-term increase in the stock price. However, the Hold rating suggests that the stock may not outperform the market significantly.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100